betamethasone topical (Rx)

Brand and Other Names:Diprolene, Luxiq, more...Dermabet, Alphatrex, Diprolene AF, Diprolene Glycol, Diprosone, Valnac, BetaVal, Sernivo
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

cream/lotion/ointment

  • 0.05%
  • 0.1%

gel

  • 0.05%

foam

  • 0.12% (Luxiq)

spray

  • 0.05% (Sernivo)

Plaque Psoriasis

Indicated for mild-to-moderate plaque psoriasis in adults

Sernivo spray: Apply to affected area(s) q12hr

Steroid-Responsive Dermatoses

Apply ointment/cream/lotion/gel (betamethasone dipropionate) qDay or q12hr

Apply ointment (betamethasone valerate) qDay or q8hr

Luxiq: Apply foam to scalp q12hr

Dosage Forms & Strengths

cream/lotion/ointment

  • 0.05%
  • 0.1%

gel

  • 0.05%

foam

  • 0.12%

Inflammatory Conditions

<12 years: Not recommended

≥12 years: Apply to affected area q12hr (low or medium potency)

Dosing considerations

  • Use minimal amount for shortest period of time to avoid HPA axis suppression

Steroid-Responsive Dermatoses

Apply ointment/cream/lotion/gel (betamethasone dipropionate) qDay or q12hr

Apply ointment (betamethasone valerate) qDay or q8hr

Next:

Adverse Effects

Frequency Not Defined

Skin atrophy

Striae

Allergic dermatitis

Burning

Dry skin

Erythema folliculitis

Hypertrichosis

Irritation

Miliaria

Vesiculation

Acneform lesions

Pigmentation changes

HPA suppression (with higher potency used >2 wk)

Postmarketing Reports

Ophthalmic: Cataracts, glaucoma, increased intraocular pressure, and central serous chorioretinopathy

Pruritus, bullous dermatitis, and erythematous rash

Previous
Next:

Warnings

Contraindications

Underlying infection present

Hypersensitivity

Ophthalmic use

Cautions

Chronic topical corticosteroid therapy may interfere with growth and development in children

Prolonged treatment with corticosteroids is associated with Kaposi sarcoma (consider discontinuation of therapy if diagnosed)

Discontinue if contact dermatitis occurs; not for use in patients with decreased skin circulation

Manifestations of Cushing syndrome, hyperglycemia, or glycosuria occur, especially if occlusive dressings are used

May increase risk of posterior subcapsular cataracts and glaucoma; cataracts and glaucoma reported postmarketing with use of topical corticosteroid products, including ointment

Use may increase risk of posterior subcapsular cataracts and glaucoma; avoid contact with eyes; advise patients to report any visual symptoms and consider referral to ophthalmologist for evaluation

Previous
Next:

Pregnancy & Lactation

Pregnancy

There are no available data on ointment use in pregnant women to identify a drug- associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy; advise pregnant women that the ointment may increase risk of having a low birthweight infant and to use it on the smallest area of skin and for the shortest duration possible

Animal data

  • In animal reproduction studies, increased malformations, including umbilical hernias, cephalocele, and cleft palate, were observed after intramuscular administration to pregnant rabbits; the available data do not allow calculation of relevant comparisons between systemic exposure in animal studies to systemic exposure that would be expected in humans after topical use of the ointment

Lactation

There are no data regarding the presence of drug in human milk, effects on breastfed infant, or on milk production after topical ointment application to women who are breastfeeding

It is possible that topical administration of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk; the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed infant drug or from underlying maternal condition

To minimize potential exposure to breastfed infant via breast milk, use ointment on smallest area of skin and for shortest duration possible while breastfeeding; advise breastfeeding women not to apply ointment directly to nipple and areola to avoid direct infant exposure

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes, inhibiting macrophage accumulation in inflamed areas, reducing leukocyte adhesion to capillary endothelium, reducing capillary wall permeability and edema formation, decreasing complement components, antagonizing histamine activity and release of kinin from substrates, and reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation

Absorption

Yes

Previous
Next:

Administration

Topical Administration

Use medium to very high potency for less than 2 weeks to reduce local and systemic side effects

Use low potency for chronic therapy

Avoid medium to very high potency on face, folds, and groin, because use in these areas can increase steroid absorption

Use lower potency for children (ie, increased BSA/kg, therefore increased systemic absorption)

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.